Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 2, 2004

View Archived Issues

H3 activation for allergic rhinitis relief

Serotonergic system involved in oleamide sleep-inducing action

IL-6 involved in myocardial dysfunction of meningococcal septic shock

Improved glycemic control found with pioglitazone plus sulfonylureas in type 2 diabetes

Efficacy and safety of subcutaneous insulin and inhaled AERx insulin in type 2 diabetes

Antitumor effects reported for erlotinib in metastatic head and neck cancer

Nestorone in contraception and hormone replacement therapy

Two novel series of prostanoid IP antagonists discovered at Bayer

Exelixis scientists present new antiangiogenic ADAM-10 inhibitors

Novel Rho kinase inhibitors prepared and tested at Bayer

New pyridazine-based PDE4 inhibitors and their use reported by Merck KGaA

New MCH antagonists for obesity and other uses claimed by Abbott

Altana and Signal scientists identify novel PKC-theta inhibitors

Dual JNK/GSK-3 inhibitors under study at Applied Research Systems

Bevacizumab inhibits tumor vascularity

A phase III trial confirms the analgesic effects of Cellegesic in chronic anal fissure

Preliminary phase III results support the use of natalizumab in Crohn's disease

Once-daily tramadol reported to provide 24-hour pain relief in osteoarthritis of the knee

Inconclusive evidence reported on the relationship between statins and fracture risk in older women

NICE issues guidance in clinical management of chronic hepatitis C

Avidex and ChemOvation extend RA collaboration

Preliminary results of phase IIb eculizumab show improvement in ACR20

New phase I trial for RSR-13 in locally advanced NSCLC

Cerus acquires mesothelin rights from Johns Hopkins University

NX-1207 produces significant clinical improvement in BPH

Phase II trials to evaluate VT-111 for ACS

New regulatory submissions for Nexium

Phase III program under way for Viramidine

Beyond Genomics and GlaxoSmithKline enter metabolic disorder collaboration

Pfizer reports significant events during past 12 months and forecasts strong growth platform

First launch for Symbyax

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Jan 30, 2025.
Today's news in brief
Briefs
BioWorld MedTech briefs for Jan. 30, 2026.
Brain-derived tau in blood predicts stroke severity and outcome
BioWorld Science
Brain-derived tau, a protein that is exclusive to the brain and detectable in the blood, could serve as an indicator of brain damage after an ischemic stroke. The...
Centessa’s CNT-9982 shows promise for MDD
BioWorld Science
Orexin OX2 receptor agonists have demonstrated the ability to enhance wakefulness in rodent models, as well as in nonhuman primates and patients with narcolepsy...
First-in-class ADC targeting DEM-TXX shows high preclinical efficacy
BioWorld Science
Researchers at DEM Biopharma Inc. reported preclinical findings demonstrating the efficacy of DEM-301, a bifunctional antibody-drug conjugate (ADC) engineered to...